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Abstract
 
The tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) induces apoptosis of tu-
mor cells but not normal cells; its role in normal nontransformed tissues is unknown. We re-
port here that chronic blockade of TRAIL in mice exacerbated autoimmune arthritis, and that
intraarticular TRAIL gene transfer ameliorated the disease. In vivo, TRAIL blockade led to
profound hyperproliferation of synovial cells and arthritogenic lymphocytes and heightened the
production of cytokines and autoantibodies. In vitro, TRAIL inhibited DNA synthesis and
prevented cell cycle progression of lymphocytes. Interestingly, TRAIL had no effect on apop-
tosis of inflammatory cells either in vivo or in vitro. Thus, unlike other members of the tumor
necrosis factor superfamily, TRAIL is a prototype inhibitor protein that inhibits autoimmune
inflammation by blocking cell cycle progression.
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Introduction
 
The TNF-related apoptosis-inducing ligand (TRAIL)
 
1
 
 is a
type II membrane protein of the TNF superfamily (1). Un-
like other members of the TNF superfamily that interact
with one or two specific receptors, TRAIL can potentially
interact with five different receptors. These include death
receptor (DR)4 (TRAIL-R1), DR5 (TRAIL-R2), decoy
receptor (DcR)1 (TRAIL-R3, TRAIL receptor without an
extracellular domain [TRID]), DcR2 (TRAIL-R4, TRAIL
receptor with a truncated death domain [TRUNDD; refer-
ences 2–8]), and a soluble receptor called osteoproteg-
erin (9).
Although the presence of multiple TRAIL receptors
strongly suggests that TRAIL is involved in multiple pro-
cesses, the precise roles of TRAIL in health and disease are
unknown. In vitro studies have shown that TRAIL induces
apoptosis of some, but not all, tumor cell lines (2, 6). This
appears to be mediated by DR4 and DR5, which possess
similar intracellular death domains as TNF receptors and
CD95 (Fas/Apo-1) and are capable of activating the caspase
cascade. The presence of DcR1 and DcR2, which do not
contain functional death domains, blocks TRAIL-induced
apoptosis (2, 6). Although both TRAIL and TRAIL recep-
tors are constitutively expressed in various tissues (1, 2, 4,
10) and are upregulated upon cell activation (5, 11, 12),
TRAIL may not induce apoptosis of most nontransformed
cells (2, 6). In vivo administration of recombinant TRAIL
selectively kills tumor cells but not normal cells, leaving the
host organ systems unharmed (13, 14). Although this find-
ing has generated tremendous interest in using recombinant
TRAIL for cancer therapy, it also raises fundamental ques-
tions regarding the roles of TRAIL in normal nontrans-
formed tissues. We report here that unlike many other
members of the TNF family, TRAIL is a potent inhibitor
of autoimmune inflammation and cell cycle progression.
 
Materials and Methods
 
Production of Recombinant DR5.
 
To generate recombinant sol-
uble (s)DR5, the cDNA that contains the full-length extracellular
domain of the human DR5 (a gift from Dr. W. El-Deiry, Uni-
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Abbreviations
 
 
 
used in this paper: 
 
Ad, adenovirus; AICD, activation-
 
induced cell death; ANOVA, analysis of variance; BrdU, bromodeoxyuri-
dine; DR, death receptor; DcR, decoy receptor; HE, hematoxylin and
eosin; HSA, human serum albumin; L, ligand; NF, nuclear factor; s, solu-
ble; TRAIL, tumor necrosis factor–related apoptosis-inducing ligand.  
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versity of Pennsylvania, Philadelphia, PA; 15) was cloned into
pGAPZ
 
a
 
 that contains a P
 
AOX1
 
 promotor and a six-histidine tag.
Several recombinant
 
 Pichia pastoris
 
 clones generated via homolo-
gous recombination (16) secreted high levels of sDR5 (up to 25
mg/liter of yeast culture). The sDR5 used in this study was puri-
fied through a nickel ion column and depleted of LPS by incuba-
tion with polymyxin B–agarose (Sigma Chemical Co.). The pu-
rity of the sDR5 was confirmed by PAGE; sDR5, which had a
mol wt of 26 kD, was the only protein band present. The purified
sDR5 contained 1–2 ng LPS/mg of protein as determined by
limulus amebocyte lysate (LAL) assay. This is comparable to the
LPS level in BSA or human serum albumin (HSA) used in this
study, which is 1–4 ng/mg of protein. In previous experiments,
we examined whether BSA or HSA had any effect on collagen-
induced arthritis using LPS-free PBS as control. No effects were
observed with respect to arthritis and anticollagen immune re-
sponses (our unpublished data; 17). In vitro, purified sDR5 did
not induce proliferation of lymphocytes regardless of its concen-
tration in the culture (1–100 
 
m
 
g/ml; our unpublished data). 
 
Generation of a Recombinant TRAIL Virus.
 
A recombinant ad-
enovirus (Ad) carrying the murine TRAIL gene (TRAIL-Ad)
was generated by inserting the cloned TRAIL full-length cDNA
into the plasmid pAdtet, followed by homologous recombination
with human adenoviral DNA (17). In brief, the murine full-
length TRAIL cDNA was generated from mouse spleen by PCR
using specific primers corresponding to the 5
 
9
 
 and 3
 
9
 
 ends of the
coding regions of the TRAIL gene. After adding A-overhangs by
incubation with Taq polymerase, the PCR fragment was inserted
into the expression vector pCRII-TOPO, which possesses T-over-
hangs, to create pCRII-TOPO-TRAIL. After amplification of
the pCRII-TOPO-TRAIL vector DNA, the TRAIL gene was
cut out with NotI and inserted into the NotI site of the vector
pAdtet to create pAdtet-TRAIL. The ClaI-digested Ad5 genomic
DNA was then prepared from H5.000CMVEGFP, a recombinant
Ad that is depleted of E1a, E1b, and a portion of E3 region but
contains the green fluorescent protein cDNA. The recombinant
virus was produced by cotransfecting 293 cells with pAdtet-
TRAIL and ClaI-digested Ad5 genomic DNA. White plaques of
recombinant viruses were expanded and screened by PCR using
TRAIL-specific primers. TRAIL-Ad was then propagated, puri-
fied through a cesium chloride gradient, and desalted on an
Econo-Pac 10DG column (Bio-Rad). In vitro, TRAIL-Ad in-
duced apoptosis of several tumor cell lines including Rat-1 cells
and 293 cells; addition of sDR5 to the culture prevented TRAIL-
Ad–induced apoptosis (Göke, A., and Y. Chen, unpublished re-
sults).
 
Induction and Examination of Arthritis.
 
6–8-wk-old male DBA/1
mice (The Jackson Laboratory) were immunized by multiple
intradermal injections of 100 
 
m
 
g chicken type II collagen (Sigma
Chemical Co.) in 100 
 
m
 
l PBS emulsified in an equal volume of
CFA containing 1 mg/ml of 
 
Mycobacterium tuberculosis 
 
H37 RA
(Difco). Mice were rechallenged with the same antigen prepara-
tion subcutaneously on the flanks 21 d later. Mice were examined
daily for signs of joint inflammation and scored as follows: 0, nor-
mal; 1, erythema and mild swelling confined to the ankle joint or
midfoot; 2, erythema and mild swelling extending from the ankle
to the midfoot; 3, erythema and moderate swelling extending
from the ankle to the metatarsal joints; 4, erythema and severe
swelling extending from the ankle to the digits. The maximal dis-
ease score per foot is 4, and the maximal disease score per mouse
is 16. The mean disease score per group is calculated as follows:
total disease scores from all animals in the group divided by the
number of animals in the group.
 
Histochemical Analysis.
 
Paws were first fixed in 10% formalin,
decalcified in hydrochloric acid, and embedded in paraffin. Joint
sections (6 
 
m
 
m) were then prepared and stained with hematoxylin
and eosin (HE). The degree of arthritic inflammation was scored
as follows: 0, no signs of inflammation; 1, mild synovitis; 2, severe
synovitis; 3, severe synovitis with mild cartilage and bone destruc-
tion; 4, severe synovitis with severe cartilage and bone destruc-
tion.
 
Bromodeoxyuridine Labeling of Proliferating Cells In Vivo.
 
Mice
were immunized twice with chicken type II collagen as described
above. Starting from the second immunization, mice received
daily intraperitoneal injections of 0.8 mg bromodeoxyuridine
(BrdU) in 0.5 ml PBS. Mice were killed 2–3 wk later, and their
synovial joints were collected and embedded in paraffin. Synovial
sections (6 
 
m
 
m) were then stained with rat anti-BrdU antibody
and peroxidase-labeled goat anti–rat IgG as described (18). Con-
trol antibodies and tissues were routinely used to exclude nonspe-
cific staining.
 
Apoptotic Studies.
 
For detection of apoptotic cells, ApopTag
 
®
 
system was used (Oncor). In brief, synovial tissues were snap-fro-
zen and cryosectioned (6 
 
m
 
m). The 3
 
9
 
-OH ends of fragmented
DNA were labeled with digoxigenin-conjugated nucleotide using
terminal deoxynucleotidyl transferase. The randomly incorporated
nucleotide polymers were then detected by peroxidase-labeled
Figure 1. Recombinant sDR5 blocks TRAIL-induced apoptosis of tu-
mor cells. Human Jurkat T cells (clone E6-1) and K562 B cells (106/ml)
were cultured in RPMI 1640 medium containing various concentrations
of TRAIL (Biomol® Research Laboratories), with or without 5 mg/ml of
sDR5. 18 h later, apoptosis was determined by flow cytometry using an-
nexin V–FITC according to the manufacturer’s instructions (PharMin-
gen). Jurkat cells were treated with either (A) 5 mg/ml of BSA, (B) 100
ng/ml of TRAIL, (C) 5 mg/ml of sDR5, or (D) 100 ng/ml of TRAIL
plus 5 mg/ml of sDR5. Each histogram represents 10,000 events, with the
apoptotic cells gated. (E) K562 cells were treated with various concentra-
tions of TRAIL with (s) or without (j) 5 mg/ml of sDR5. The per-
centage of apoptotic cells was determined as shown above in A–D. In
parallel experiments, we also tested whether sDR5 blocked Fas- and ul-
traviolet-induced apoptosis of Jurkat cells; no effect of sDR5 on apoptosis
was detected in these systems (our unpublished data). 
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antidigoxigenin antibody and the chromogen diaminobenzidin.
Counterstain was performed with methyl green. The apoptotic
index was recorded as follows: 0, 
 
,
 
1% of cells in the synovium
are apoptotic; 1, 1–3% of cells in the synovium are apoptotic; 2,
3.1–5% of cells in the synovium are apoptotic; 3, 
 
.
 
5% of cells in
the synovium are apoptotic.
 
Results
 
Recombinant sDR5 Blocks TRAIL-induced Apoptosis of Tu-
mor Cells.
 
To determine the biological roles of TRAIL in
vivo and in vitro, we produced large quantities of sDR5
using the yeast 
 
P. pastoris
 
 system (16). The sDR5 consists
only of the extracellular domain of the human TRAIL re-
ceptor DR5, and effectively blocks TRAIL-induced apop-
tosis of tumor cells. Fig. 1, A–D, illustrates the effect of
 
sDR5 on TRAIL-induced apoptosis of Jurkat T leukemia
cells, and Fig. 1 E demonstrates dose-dependent killing of
B lymphoma cells by TRAIL, and its blockade by sDR5.
 
Roles of TRAIL in Autoimmune Arthritis.
 
The effect of
TRAIL blockade in vivo was first examined in a mouse
model of rheumatoid arthritis (Fig. 2). DBA/1 mice were
immunized to induce arthritis on days 0 and 21 with
chicken type II collagen. Starting from day 21, mice were
injected daily with either 100 
 
m
 
g sDR5 or a control pro-
tein (such as BSA or HSA). Arthritis was monitored by
both clinical examination and histochemistry. As shown in
Fig. 2 A, mice that received the control protein developed
typical arthritis, which started 
 
z
 
10 d after the second im-
munization, and reached a maximal disease score of 7.8 by
day 33. By contrast, in mice treated with sDR5, arthritis
was significantly exacerbated. The mean day of onset in the
sDR5-treated group was 7.5 
 
6 
 
1.9 (days after second im-
munization), compared with 14.5 
 
6 
 
1.8 in the control
group (
 
P
 
 , 
 
0.01 as determined by ANOVA). The maximal
disease score was increased from 7.8 in the control group to
12.4 in the sDR5-treated group. Fig. 2 B illustrates the
dose-dependent effect of sDR5 on arthritis as judged by
disease score per foot. It is apparent that sDR5 enhanced
arthritic inflammation in most feet in a dose-dependent
manner.
These results indicate that TRAIL may be an inhibitor of
autoimmune arthritis. To directly test this theory, we per-
formed intraarticular TRAIL gene transfer using a replica-
tion-defective Ad carrying the mouse TRAIL gene. The
Figure 2. Exacerbation of collagen-induced arthritis by TRAIL
blockade. Groups of DBA/1 mice (four to six per group) were immu-
nized on days 0 and 21 with chicken type II collagen as described in Ma-
terials and Methods. Starting from the second immunization, mice re-
ceived daily intraperitoneal injections of 50–300 mg sDR5 or BSA in 0.5
ml PBS for a total of 21 d (in parallel experiments, other control proteins
such as HSA were also used; similar results as reported here were ob-
served). (A) Disease courses in mice treated with 100 mg of BSA (h) or
sDR5 (d). Each data point represents a mean 6 SD from a total of five
(for sDR5-treated group) or six (for BSA-treated group) mice. The ex-
periments were repeated five times with similar results. The differences
between the two groups are statistically significant (P , 0.001) as deter-
mined by Mann-Whitney test. (B) Disease scores of individual feet 12 d
after the second immunization. A total of four groups of mice are shown:
one was treated with 100 mg BSA, and the other three were treated with
50–300 mg sDR5. Each data point represents an individual foot, with
16–24 feet per group. The differences between BSA- and sDR5-treated
groups are statistically significant as determined by ANOVA (P , 0.05
for mice treated with 50 mg sDR5, and P , 0.01 for mice treated with
100 or 300 mg sDR5).
Figure 3. Inhibition of collagen-induced arthritis by TRAIL gene
transfer. DBA/1 mice (four per group) were immunized with type II col-
lagen as described in Materials and Methods. 6 d after the disease onset
(10 d after the second immunization), mice were injected intraarticularly
and periarticularly to the ankle and tarsal joints of the hind feet with (1)
10 ml PBS (control), (2) 1010 particles of Ad vector (the Ad vector con-
tains no TRAIL gene but is otherwise identical to the TRAIL virus), (3)
109 particles of TRAIL virus, or (4) 1010 particles of TRAIL virus in 10 ml
of PBS (reference 17). Starting from the day of the viral injection, two
groups of mice, one nontreated and the other injected with 1010 particles
of TRAIL virus, were subjected to daily intraperitoneal injections of 100
mg sDR5 for a total of 14 d. Data presented are disease scores of individ-
ual hind feet 6 d after viral injection. A total of eight hind feet per group
are shown. Only mice that received 1010 particles of TRAIL virus showed
significant improvement (P , 0.001 as determined by ANOVA). Results
are representative of two experiments. 
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virus was injected directly into arthritic joints 6 d after dis-
ease onset as described previously (17). As shown in Fig. 3,
arthritis was dramatically ameliorated after intraarticular in-
jection of 10
 
10
 
 recombinant TRAIL viruses. Injection of
10
 
9
 
 recombinant TRAIL viruses had only a mild effect.
The effect of the treatment was TRAIL specific, as it can
be neutralized by sDR5 (Fig. 3). The therapeutic effect of
the TRAIL virus lasted 
 
z
 
10 d, and arthritis returned 
 
z
 
2
wk after TRAIL virus injection. As expected, injection of
sDR5 after the disease onset also exacerbated the inflam-
mation (Fig. 3).
Histochemical analysis of mice treated as described
above revealed dramatic differences between the groups.
In mice treated with control protein, arthritis was charac-
terized by leukocyte infiltration, mild synovitis, and pan-
nus formation (Fig. 4, A and C); cartilage destruction and
 
bone erosion occurred only in a small number of synovial
joints. By contrast, in mice treated with sDR5, severe sy-
novitis, hyperplasia of synovial membrane, and cartilage
and/or bone destruction were observed in most synovial
joints of the feet (Fig. 4, B and D) and lasted for 
 
.
 
3 wk
with few signs of remodeling or fibrosis. To directly label
proliferating cells in the joint, we treated mice with nucle-
otide analogue BrdU and examined BrdU incorporation
by immunohistochemistry. As shown in Fig. 4, E and F,
BrdU
 
1
 
 cells were detected in both BSA- and sDR5-treated
mice, but the number of BrdU
 
1
 
 cells in sDR5-treated mice
was markedly increased compared with BSA-treated
mice. Quantitative analysis of the histochemical data re-
vealed significant differences between sDR5- and BSA-
treated groups (pathology score 3.9 vs. 2.8,
 
 P 
 
, 
 
0.01;
Fig. 5 A).
Figure 4. Histochemical profiles of arthritic
joints. DBA/1 mice (eight to nine per group) were
immunized for arthritis and treated with sDR5 or
BSA as described in the legend to Fig. 2 A. For A–D,
G, and H, mice were killed 32 d after the second
immunization, and their ankle joints were ana-
lyzed for histology and apoptosis as described in
Materials and Methods. For E and F, mice were in-
jected intraperitoneally with BrdU as described in
Materials and Methods, and were killed 21 d after
the second immunization. BrdU staining was per-
formed as described in Materials and Methods. (A)
An ankle joint of a BSA-treated mouse with a pa-
thology score of 2 (HE staining; original magnifica-
tion: 320). Arrow indicates signs of synovitis. (B)
An ankle joint of an sDR5-treated mouse with a
pathology score of 4 (HE staining; original magnifi-
cation: 320). Arrows indicate severe synovitis, hy-
perplasia, and cartilage and bone destruction. (C)
An ankle joint of a BSA-treated mouse with a pa-
thology score of 1 (HE staining; original magnifica-
tion: 3100). Arrow indicates signs of synovitis. (D)
An ankle joint of an sDR5-treated mouse with a
pathology score of 4 (HE staining; original magnifi-
cation:  3100). Arrows indicate severe synovitis,
hyperplasia, and cartilage and bone destruction. (E)
An ankle joint of a BSA-treated mouse with a dis-
ease score of 2 (BrdU staining; original magnifica-
tion: 3400). Arrows indicate BrdU1 nuclei, which
are shown in brown. (F) An ankle joint of an
sDR5-treated mouse with a disease score of 3
(BrdU staining; original magnification: 3400). (G)
An ankle joint of a BSA-treated mouse with a pa-
thology score of 4 (apoptotic staining; original mag-
nification: 3200). Arrows indicate apoptotic cells,
which are shown in brown. (H) An ankle joint of
an sDR5-treated mouse with a pathology score of 4
(apoptotic staining; original magnification: 3200). 
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Roles of TRAIL in Autoimmune T and B Cell Responses In
Vivo.
 
Collagen-induced arthritis is initiated by collagen-
specific lymphocytes. To determine whether exacerbation
of arthritis by sDR5 is associated with functional alter-
ations of collagen-specific lymphocytes, we examined
both cellular and humoral anticollagen immune responses.
Mice were treated as described above, and their blood and
lymphoid tissues were collected 2–6 wk after immuniza-
tion. As shown in Fig. 6, A–C, lymph node cells from
control mice proliferated moderately in response to col-
lagen and produced both IL-2 and IFN-
 
g
 
. Remarkably,
both lymphocyte proliferation and cytokine production
were enhanced in mice treated with sDR5. Con A–treated
cultures were included as positive controls to illustrate the
levels of polyclonal T cell responses. Anticollagen antibody
responses were determined by collagen-specific ELISA as
in Fig. 6, D and E. Anticollagen IgG2a was dramatically
increased in mice treated with sDR5, whereas anticollagen
IgG1 was only moderately increased on day 14. These re-
sults indicate that chronic TRAIL blockade in mice en-
hanced both cellular and humoral immune responses,
which might in turn exacerbate autoimmune arthritis. It is
to be noted that short-term TRAIL blockade in DBA/1
Figure 5. Pathological and apoptotic studies of arthritic joints. Mice
were treated and killed as described in the legend to Fig. 4, and their paws
were examined for the degrees of inflammation and apoptosis as described
in Materials and Methods. A minimum of three comparable synovial sec-
tions per mouse were analyzed. A total of eight (for sDR5-treated group)
and nine (for BSA-treated group) mice were used. For pathology scores
(A), the differences between the two groups are statistically significant as
determined by ANOVA (P , 0.01). For apoptotic index (B), the differ-
ences between the two groups are not statistically significant as deter-
mined by ANOVA (P 5 0.21).
Figure 6. Effect of TRAIL blockade
on anticollagen immune responses.
DBA/1 mice (five to six per group)
were treated as described in the legend
to Fig. 2 A. To test cellular immune re-
sponses (A–C), mice were killed 32 d af-
ter the second immunization, and their
inguinal lymph nodes were collected.
For cytokine assays, lymph node cells
(1.5 3 106 per well) were cultured in
0.2 ml of serum-free medium (X-vivo
20; BioWhittaker) with or without 10–
50 mg/ml of chicken type II collagen
(CII) or 1 mg/ml of Con A. Culture su-
pernatants were collected 40 h later, and
IL-2/IFN-g concentrations were deter-
mined by sandwich ELISA as described
(reference 46). To test lymphocyte proliferation (A), lymph node cells (0.5 3 106 cells
per well) were first cultured for 72 h, then pulsed with [3H]thymidine for an addi-
tional 16 h. Radioactivity (presented as cpm) was determined using a Wallac b-plate
counter. To test humoral immune responses (D and E), mice were bled retroorbitally
14 and 32 d after the second immunization, and anticollagen IgG1 and IgG2a antibod-
ies were determined by ELISA using chicken type II collagen as antigen. Each data
point represents a mean 6 SD from five (for sDR5-treated group) or six (for BSA-
treated group) mice. The experiments were repeated three times with similar results.
When a similar ELISA was performed using sDR5 as detecting antigen, no anti-sDR5
antibodies were detected (data not shown). In parallel experiments, mice were killed
14 and 21 d after the second immunization, and were tested as described in A–C. Sim-
ilar differences between control and sDR5-treated mice were observed (data not
shown). Additionally, sDR5 had no effect on LPS-induced proliferation of spleno-
cytes in vitro (our unpublished data). (A) Proliferative responses as determined by
[3H]thymidine incorporation. (B) IL-2 production. (C) IFN-g production. (D) Anti-
collagen IgG2a titers. (E) Anticollagen IgG1 titers. White bars, mice treated with BSA;
black bars, mice treated with sDR5. 
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mice did not alter the structure or cellular composition of
lymphoid organs as judged by histochemistry and flow cy-
tometry (our unpublished data).
 
Roles of TRAIL in Apoptosis and Cell Cycle Progression.
 
Some members of the TNF family are capable of inducing
apoptosis of normal and/or tumor cells. TRAIL has been
shown to induce apoptosis of some, but not all, tumor cell
lines (2–8). The effect of sDR5 on arthritis can be ex-
plained by its blockade of TRAIL-induced apoptosis of
inflammatory cells. To test this theory, we first examined
the effect of TRAIL blockade on apoptosis of synovial
cells in vivo. As shown in Fig. 4, G and H, apoptotic cells
were readily detectable in arthritic synovia of both control
and sDR5-treated mice 32 d after the second immuniza-
tion. However, no statistically significant differences be-
tween the two groups were observed when the degrees of
apoptosis were compared (Fig. 5 B). In parallel experi-
ments, mice were also killed 14 and 21 d after the second
immunization and examined for apoptosis as in Fig. 4, G
and H. Again, no significant differences in the degree of
apoptosis were observed between control and sDR5-
treated groups (data not shown). Both TNF and CD95
ligand (CD95L) have been shown to mediate activation-
induced cell death (AICD) of lymphocytes (19–21).
Therefore, we also examined the role of TRAIL in the
death and survival of lymphocytes (Fig. 7). Splenocytes
were isolated from BALB/c mice and activated in vitro
with Con A for 3 d. Live cells were then purified through
a Ficoll gradient and restimulated in vitro with anti-CD3
mAb. Apoptosis and cell cycle progression were analyzed
by flow cytometry using the DNA dye propidium iodide
(22). As shown in Fig. 7 A, anti-CD3 mAb induced apop-
tosis of 
 
z
 
16% of the cells; this was completely prevented
by anti-CD95L mAb, confirming an essential role for
CD95L in AICD (19–21). By contrast, sDR5 moderately
increased AICD induced by anti-CD3 mAb (Fig. 7 A).
Unexpectedly, the total number of cells, especially cells in
the S-G2/M phases of the cell cycle, were dramatically in-
creased in cultures containing sDR5 (Fig. 7 B). This in-
crease in S-G2/M cells was TRAIL specific, as it was par-
tially blocked by recombinant TRAIL (Fig. 7 B). These
results strongly suggest that although TRAIL may not in-
duce apoptosis of lymphocytes, it does play important
roles in regulating cell cycle progression. To test this the-
ory directly, we examined the effect of recombinant
TRAIL and sDR5 on cell cycle progression of lympho-
cytes. T lymphocytes were stimulated with anti-CD3
mAb as in Fig. 7 A, and G1 to S phase progression was
determined by [
 
3
 
H]thymidine incorporation (cells enter-
ing the S phase of the cell cycle synthesize DNA and take
up thymidine). As shown in Fig. 7, C and D, anti-CD3
mAb induced a marked increase in thymidine uptake.
This was significantly inhibited by TRAIL (Fig. 7 C) but
enhanced by sDR5 (Fig. 7 D). Again, neither TRAIL nor
sDR5 affected apoptosis of cells in the culture (our un-
published data). Studies are underway to elucidate the in-
tracellular signaling pathways that are responsible for
Figure 7. Inhibition of DNA synthesis and cell cycle progression by
TRAIL. Splenocytes were prepared from 6–8-wk-old BALB/c mice (The
Jackson Laboratory) and cultured in DMEM for 3 d in the presence of
10% FBS and 2.5 mg/ml of Con A. Live cells were then purified through
a Ficoll gradient and cultured in 96-well plates at 3 3 105 cells per well in
200 ml of DMEM containing 10% FBS, with or without the following re-
agents: 100 ng/ml of TRAIL, 5 mg/ml of sDR5, 5 mg/ml of anti-CD95L
mAb (MFL-3), and anti–mouse CD3 mAb (which was coated on the
plate by preincubating the plate with 10 mg/ml of the antibody at 48C for
16 h). For apoptosis and cell cycle analyses (A and B), cells were cultured
for a total of 24 h, fixed in 70% ethanol, and stained with 50 mg/ml of
propidium iodide. For thymidine incorporation assays (C and D), cells
were cultured for 24 h, then pulsed with 10 mCi/ml of [3H]thymidine for
an additional 16 h. Cells were then harvested, and radioactivity was deter-
mined using a Wallac b-plate counter. (A) Percentage of apoptotic cells as
determined by flow cytometry. The spontaneous apoptotic rate in cultures
containing no anti-CD3 mAb was 12%, which was subtracted from the
data presented here. For cultures that contained TRAIL and anti-CD3
mAb, the percentage of anti-CD3–induced apoptosis was 16 6 1%, which
was comparable to that of the cultures treated with anti-CD3 mAb alone.
The differences between anti-CD95L mAb–treated culture and all other
cultures are statistically significant as determined by ANOVA (P ,
0.0001). (B) Number of S-G2/M cells per well as determined by flow cy-
tometry. For cultures that contained TRAIL and anti-CD3 mAb, the
number of cells in the S-G2/M phases was 70–90% of that of the anti-
CD3 mAb–treated culture. The total numbers of live cells per well recov-
ered from each group were as follows: cultures with anti-CD3 mAb alone,
0.3 3 105; cultures with anti-CD3 mAb plus sDR5, 1.6 3 105; cultures
with anti-CD3 mAb plus anti-CD95L mAb, 1.1 3 105; cultures with
anti-CD3 mAb plus sDR5 plus TRAIL, 0.6 3 105. The differences be-
tween all four groups are statistically significant as determined by ANOVA
(P , 0.01). (C and D) DNA synthesis as determined by [3H]thymidine in-
corporation. Data presented are means cpm 6 SD of triplicate cultures.
For cultures containing anti-CD3 mAb, the differences between the two
groups are statistically significant as determined by ANOVA (P , 0.01).
The experiments were repeated twice with similar results. The concentra-
tions of TRAIL and sDR5 used in these experiments were selected based
on the dose-dependency studies performed in our laboratory. When 0.2–1
mg/ml of sDR5 was used, less significant effects on cell cycle progression
were observed. Similarly, when 50–150 ng/ml of TRAIL was tested,
much less significant effects on cell cycle were detected (data not shown).
TRAIL-mediated cell cycle inhibition. As AICD is regu-
lated by cell cycle progression, inhibition of cell cycle by
TRAIL may modulate the sensitivity of cells to AICD as
shown in Fig. 7 A.1101 Song et al.
Discussion
Although it has been established that TRAIL induces ap-
optosis of tumor cells but not normal cells, the roles of
TRAIL in health and disease are virtually unknown. Re-
sults presented here strongly suggest that TRAIL is a potent
inhibitor of autoimmune arthritis. The inhibitory effect of
TRAIL on arthritis may be a result of inhibition of cell cy-
cle progression and/or cytokine production. Blocking en-
dogenous TRAIL with sDR5 eliminates this inhibition and
enhances proliferation of autoreactive lymphocytes (as
shown in Fig. 6 A) or synovial cells (as shown in Fig. 4).
This may in turn contribute to the exacerbation of arthritic
inflammation and joint tissue destruction.
Thus, one of the functions of TRAIL in vivo is to main-
tain immune homeostasis and to downregulate immune re-
sponses, including autoimmune responses. This is in star-
tling contrast to TNF, which initiates and exacerbates
autoimmune diseases. In fact, anti-TNF therapy is effective
in preventing arthritic inflammation both in humans and
animals (23–26). Results reported here indicate that the
role of TRAIL in autoimmunity may be more closely re-
lated to that of CD95L or CD30L. Mutations in CD95/
CD95L genes lead to the development of systemic autoim-
mune diseases in both humans (27, 28) and mice (29–32),
although they paradoxically prevent several organ-specific
autoimmune diseases (33–39). We and others have shown
that upregulating CD95 or CD95L function in synovial
joints ameliorates autoimmune arthritis (17, 40). Similarly,
CD30L may also play an antiinflammatory role in autoim-
mune diseases (41). Autoreactive CD81 T cells deficient in
CD30L elicit more severe autoimmune insulitis in mice
(41). Thus, unlike TNF but similar to CD95L and CD30L,
TRAIL may be a member of an inhibitor protein subfamily
that prevents autoimmune diseases by downregulating im-
mune responses.
However, our results also indicate that the mechanism of
TRAIL action in vivo is different from that of CD95L.
Whereas CD95L induces apoptosis of activated T cells,
TRAIL appears to inhibit their proliferation without elimi-
nating them through apoptosis. This finding is consistent
with recent reports that, unlike CD95L, TRAIL induces
apoptosis of tumor cells but not normal cells (2, 6). Sys-
temic administration of recombinant TRAIL, but not
CD95L, selectively kills tumor cells while sparing normal
host cells (13, 14). Our observation that TRAIL can inhibit
DNA synthesis provides direct evidence that TRAIL can
prevent G1 to S phase progression of lymphocytes. There-
fore, we propose that unlike TNF or CD95L, TRAIL in-
hibits activation and expansion of lymphocytes in vivo, but
does not delete them from the system. The molecular basis
of TRAIL-induced inhibition of cell cycle progression
needs to be further examined. It has been reported that
some of the TRAIL receptors can activate both caspase
(through Fas-associated death domain protein [FADD]/
TNF receptor 1–associated death domain protein
[TRADD]) and nuclear factor (NF)-kB pathways in tumor
cells (42–44). Therefore, it is necessary to determine
whether this also occurs in normal cells, and if so, whether
this is responsible for the cell cycle–arresting effect reported
here. It is to be noted that NF-kB activation occurs in col-
lagen-induced arthritis, and that inhibition of NF-kB acti-
vation in T cells prevents the disease (45). On the other
hand, various signal transduction pathways of TRAIL re-
ceptors are yet to be defined. Novel unidentified pathways
may be responsible for the inhibitory effect of TRAIL in
inflammation and cell cycle progression.
In summary, we have established that TRAIL, unlike its
apoptotic effect on tumor cells, inhibits cell cycle progres-
sion of nontransformed lymphocytes, and that unlike TNF,
which promotes inflammation, TRAIL inhibits autoim-
mune inflammation and prevents self-tissue destruction.
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